Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study).
- DOI
- 10.1016/j.esmoop.2026.108302
- Published
- 2026 Jul
- Container
- ESMO open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.esmoop.2026.108302,
title = {Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study).},
author = {Roviello G and Ciccimarra F and Urabe F and Melichar B and Studentova H and Niedersuess-Beke D and Mota A and Büttner T and Gómez de Liaño A and Yano A and Myint ZW and Kopp RM and Zgura A and Pinto A and Angel M and Tural D and Kanesvaran R and Ürün Y and Molina-Cerrillo J and Marques Monteiro FS and Massari F and Fiala O and Santoni M and Antonuzzo L and Rizzo A},
year = {2026},
journal = {ESMO open},
doi = {10.1016/j.esmoop.2026.108302},
url = {https://doi.org/10.1016/j.esmoop.2026.108302}
}RIS
TY - JOUR TI - Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study). AU - Roviello G AU - Ciccimarra F AU - Urabe F AU - Melichar B AU - Studentova H AU - Niedersuess-Beke D AU - Mota A AU - Büttner T AU - Gómez de Liaño A AU - Yano A AU - Myint ZW AU - Kopp RM AU - Zgura A AU - Pinto A AU - Angel M AU - Tural D AU - Kanesvaran R AU - Ürün Y AU - Molina-Cerrillo J AU - Marques Monteiro FS AU - Massari F AU - Fiala O AU - Santoni M AU - Antonuzzo L AU - Rizzo A PY - 2026 JO - ESMO open DO - 10.1016/j.esmoop.2026.108302 UR - https://doi.org/10.1016/j.esmoop.2026.108302 ER -
APA
G, R., F, C., F, U., B, M., H, S., D, N., A, M., T, B., A, G. D. L., A, Y., ZW, M., RM, K., A, Z., A, P., M, A., D, T., R, K., Y, Ü., J, M., FS, M. M., F, M., O, F., M, S., L, A., & A, R. (2026). Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study).. ESMO open. https://doi.org/10.1016/j.esmoop.2026.108302
Source records
- pubmed · retrieved 2026-09-26T06:46:38.468Z